In a nutshell This study reviewed treatment recommendations for elderly diffuse large B-cell lymphoma patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common form of NHL in older patients. Many of these patients are over the age of 65. Chemotherapy is the standard treatment option for DLBCL. Many chemotherapies...
Read MoreIn a nutshell This study reported on the long-term outcome of intensive immunochemotherapy and stem cell transplantation in patients with mantle cell lymphoma. This study concluded that long-term results were encouraging but highlighted the need for personalized treatment options. Some background The combination of intensive chemotherapy combined...
Read More
In a nutshell This study examined the effectiveness of adding rituximab (Rituxan) to chemotherapy combinations. This study concluded that this combination was safe and effective in mantle cell lymphoma. Some background There is no standard treatment for newly diagnosed younger (less than 65) patients with mantle cell lymphoma. Cytarabine-based...
Read MoreIn a nutshell This study reviewed the use of lenalidomide (Revlimid) in B-cell non-Hodgkin lymphomas. Some background Non-Hodgkin lymphoma (NHL) is a highly treatable and curable form of cancer. NHL can be slow-growing, such as follicular lymphoma (FL). It can also be aggressive, such as diffuse large B-cell lymphoma (DLBCL). Both types are...
Read More
In a nutshell This study examined the development of a prognostic score that could help in predicting patient outcome in follicular lymphoma (FL). This study determined that the FL International Prognostic Index they developed could be useful in choosing treatments and predicting outcome. Some background Follicular lymphoma is an indolent...
Read More
In a nutshell This article reviewed the role of PET (positron emission tomography) scans in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Some background PET scans have been used for years to measure cancer activity in patients with DLBCL. Its use in FL has only recently been considered. In an FDG-PET scan, glucose is...
Read More
In a nutshell This study compared the outcomes of different treatment options for stage 1 follicular lymphoma (FL). This study concluded that different treatment approaches were all associated with good outcomes. Some background FL is the second most common form of non-Hodgkin lymphoma diagnosed in the United States. 26% of patients are...
Read More
In a nutshell This study explored the accuracy and predictive power of FDG-PET/CT scans for measuring remaining disease after treatment in childhood non-Hodgkin lymphoma (NHL). This study determined that a negative scan was predictive of remission, but there was a high false positive rate. Some background FDG-PET scans measure regional glucose...
Read More
In a nutshell This study examined whether maintenance (long-term) therapy with rituximab (Rituxan) was safe and effective in patients with follicular lymphoma. This study concluded that rituximab improved progression free survival (time from treatment until disease progression). Some background Follicular lymphoma is the second most common form of...
Read More
In a nutshell This study discussed an updated method for predicting outcome in patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that this new method was more accurate. Some background The International Prognostic Index (IPI) has been used to predict outcome in DLBCL patients for more than 20 years. It takes five patient...
Read More
In a nutshell This study reviewed updated guidelines for the staging and treatment of diffuse large B-cell lymphoma (DLBCL). Some background DLBCL accounts for 30%–58% of non-Hodgkin lymphomas. In recent years there have been improvements in the treatment of DLBCL. The European Society for Medical Oncology (ESMO) recently gathered a...
Read More
In a nutshell This study compared different chemotherapy regimens and rituximab (Rituxan) for the initial treatment of advanced follicular lymphoma. This study concluded that the combinations R-CHOP and R-FM were more effective than R-CVP. R-CHOP was associated with fewer severe side effects than R-FM. Some background Follicular lymphoma (FL) is...
Read More
